Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships
Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management. Dr. Scanlon also says that there is a lot of variation in the cost and quality of care in oncology. The goal is to identify the appropriate payments for quality care.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
As the healthcare industry moves to a more consumerism based environment, the number one goal for health plans is to have affordable options, explained Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.
In this segment, the panelists analyze current programs that aim to educate and guide key stakeholders through the facets of cancer care and conclude that collaboration can help control costs and drive quality.
Although not often included in pathways due to their recent introduction into clinical practice, immunotherapies are playing important roles in the treatment of many types of cancer. In this segment, the panelists discuss the use of immunotherapies and how to evaluate safety in the context of pathways.
Providers consider many factors when selecting a branded oncology drug over a generic, comment Drs Michael Kolodziej and Ira Klein. The panel continues their discussion addressing concerns over toxicity, safety, and cost.
In this segment, Christopher Sweeney, MBBS, discusses the results of the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED). Dr Sweeney also discusses how the results of CHAARTED have impacted the treatment of patients with prostate cancer and influenced research on combination therapy.
Christopher Sweeney, MBBS, describes 2 patient cases that demonstrate the variability in disease course among patients with castration-resistant prostate cancer and explains how variability affects treatment decisions. Dr Sweeney also discusses the emergence of a promising biomarker to help determine whether or not a patient would respond to hormonal therapy.
Christopher Sweeney, MBBS, provides an overview of castration-resistant prostate cancer and discusses criteria that clinicians consider when making decisions about treatment for patients who experience disease progression.